Marshall Wace, LLP Denali Therapeutics Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

A detailed history of Marshall Wace, LLP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,967,141 shares of DNLI stock, worth $45.8 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
1,967,141
Previous 2,418,833 18.67%
Holding current value
$45.8 Million
Previous $56.2 Million 2.02%
% of portfolio
0.07%
Previous 0.08%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$20.96 - $31.05 $9.47 Million - $14 Million
-451,692 Reduced 18.67%
1,967,141 $57.3 Million
Q2 2024

Aug 14, 2024
BUY
$14.96 - $23.22 $4.08 Million - $6.33 Million
272,454 Added 12.69%
2,418,833 $56.2 Million
Q1 2024

May 15, 2024
BUY
$15.83 - $23.35 $7.58 Million - $11.2 Million
478,982 Added 28.73%
2,146,379 $44 Million
Q4 2023

Feb 14, 2024
BUY
$16.2 - $23.18 $27 Million - $38.7 Million
1,667,397 New
1,667,397 $35.8 Million
Q1 2023

May 15, 2023
SELL
$21.91 - $32.67 $13.4 Million - $19.9 Million
-610,100 Reduced 63.51%
350,539 $8.08 Million
Q4 2022

Feb 14, 2023
BUY
$26.28 - $33.92 $7.48 Million - $9.66 Million
284,769 Added 42.13%
960,639 $26.7 Million
Q3 2022

Nov 14, 2022
SELL
$25.97 - $38.53 $3.68 Million - $5.46 Million
-141,780 Reduced 17.34%
675,870 $20.7 Million
Q2 2022

Aug 15, 2022
BUY
$20.88 - $35.19 $13.9 Million - $23.4 Million
664,795 Added 434.92%
817,650 $24.1 Million
Q1 2022

May 16, 2022
SELL
$29.0 - $47.27 $6.7 Million - $10.9 Million
-231,089 Reduced 60.19%
152,855 $4.92 Million
Q4 2021

Feb 14, 2022
SELL
$42.59 - $55.02 $6.28 Million - $8.11 Million
-147,414 Reduced 27.74%
383,944 $17.1 Million
Q3 2021

Nov 15, 2021
SELL
$48.48 - $78.23 $5.56 Million - $8.97 Million
-114,641 Reduced 17.75%
531,358 $26.8 Million
Q2 2021

Aug 13, 2021
BUY
$50.3 - $78.44 $27.5 Million - $42.9 Million
546,481 Added 549.13%
645,999 $50.7 Million
Q1 2021

May 17, 2021
BUY
$53.8 - $81.53 $5.35 Million - $8.11 Million
99,518 New
99,518 $5.68 Million
Q4 2020

Feb 16, 2021
SELL
$36.89 - $93.56 $12 Million - $30.4 Million
-325,168 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$23.13 - $38.84 $6.63 Million - $11.1 Million
286,598 Added 743.06%
325,168 $11.7 Million
Q2 2020

Aug 13, 2020
SELL
$16.01 - $28.82 $3.26 Million - $5.87 Million
-203,550 Reduced 84.07%
38,570 $933,000
Q1 2020

May 15, 2020
BUY
$14.2 - $27.98 $2.78 Million - $5.48 Million
195,743 Added 422.07%
242,120 $4.24 Million
Q4 2019

Feb 14, 2020
BUY
$14.4 - $19.99 $667,828 - $927,076
46,377 New
46,377 $808,000
Q2 2019

Aug 14, 2019
SELL
$18.5 - $28.14 $286,250 - $435,410
-15,473 Closed
0 $0
Q1 2019

May 14, 2019
BUY
$17.99 - $24.65 $278,359 - $381,409
15,473 New
15,473 $359,000

Others Institutions Holding DNLI

# of Institutions
227
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.12B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email